Author

K. O. Barbosa

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Assay:ChIP-seq· 1 Assay:DNA methylation· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Deshpande· 2 shared A. Bagchi· 1 shared A. Rosa Campos· 1 shared B. Chen· 1 shared B. M. Ryan· 1 shared C. J. Eaves· 1 shared D. Frank· 1 shared D. M. Wilson· 1 shared

Activity by Year

2019-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Deshpande

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A JAK/STAT-Mediated Inflammatory Signaling Cascade Drives Oncogenesis In AF10-Rearranged AML

B. Chen, A. Deshpande, K. O. Barbosa, M. Kleppe, X. Lei, N. Yeddula, A. Rosa Campos, R. Wechsler-Reya, A. Bagchi, S. Meshinchi, C. J. Eaves, I. Jeremias, T. Haferlach, D. Frank, Z. Ronai, , A. Deshpande

This study identifies JAK1 as a therapeutic target in AF10-rearranged AML by showing its role in JAK/STAT-mediated inflammatory signaling and oncogenesis.

bioRxiv · Aug 31, 2020Cancer Biology

Integrated computational and experimental identification of p53, KRAS and VHL mutant selection associated with CRISPR-Cas9 editing

S. Sinha, K. O. Barbosa, K. Cheng, M. D. Leiserson, D. M. Wilson, B. M. Ryan, Z. A. Ronai, J. S. Lee, A. Deshpande, E. Ruppin

The paper identifies p53, KRAS, and VHL mutations as being selected during CRISPR-Cas9 editing through computational and experimental analysis.

bioRxiv · Nov 2, 2019 · PreprintCancer Biology